CCL2: A Promising Drug Target for Cancer and Other Diseases (G6347)

Target Name: CCL2

NCBI ID: G6347

CCL2

CCL2: A Promising Drug Target for Cancer and Other Diseases

CCL2 (Complement Component 2) is a protein that is expressed in various tissues throughout the body, including the skin, heart, liver, and spleen. It is a key component of the complement system, which is a group of proteins that work together to help the immune system fight off infections.

One of the things that makes CCL2 an interesting drug target is its role in the development of cancer. Studies have shown that high levels of CCL2 have been associated with the development of a variety of cancers, including breast, ovarian, and prostate cancers.

In addition, CCL2 has also been shown to play a role in the regulation of cell growth and division. This is important because abnormal cell growth and division can lead to the development of cancer. By targeting CCL2, researchers may be able to inhibit the growth and division of cancer cells.

Another potential mechanism by which CCL2 may contribute to the development of cancer is its role in the development of blood-borne diseases. CCL2 has been shown to be expressed in the bloodstream, which suggests that it may be involved in the transmission of certain diseases. For example, some studies have suggested that CCL2 may be involved in the development of heart disease and liver cancer due to its role in the regulation of blood flow.

Despite these potential connections to cancer and other diseases, much more research is needed before CCL2 can be fully understood as a drug target. In the meantime, researchers are still studying its role in various biological processes, including the regulation of inflammation and the immune response.

Overall, CCL2 is an intriguing drug target due to its potential involvement in the development of cancer and other diseases. As more research is done to understand its role, it may be able to provide new insights into the underlying mechanisms of these diseases and lead to the development of new treatments.

Protein Name: C-C Motif Chemokine Ligand 2

Functions: Acts as a ligand for C-C chemokine receptor CCR2 (PubMed:9837883, PubMed:10587439, PubMed:10529171). Signals through binding and activation of CCR2 and induces a strong chemotactic response and mobilization of intracellular calcium ions (PubMed:9837883, PubMed:10587439). Exhibits a chemotactic activity for monocytes and basophils but not neutrophils or eosinophils (PubMed:8627182, PubMed:9792674, PubMed:8195247). May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis (PubMed:8107690)

The "CCL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets